Additionally, when differentiating BC from patients with non-urothelial malignancies, the AUCs of the Vimentin/POU4F2 methylation panel in the validation set were 0.932 (95% CI: 0.883–0.981) (Fig. 4B). The gene discussed is POU4F2; the disease is breast cancer.